Rice Hall James & Associates LLC acquired a new position in Omnicell, Inc. (NASDAQ:OMCL – Free Report) during the second quarter, HoldingsChannel.com reports. The fund acquired 51,789 shares of the company’s stock, valued at approximately $2,150,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in OMCL. Dimensional Fund Advisors LP raised its holdings in Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after purchasing an additional 137,834 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Omnicell by 156.4% in the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the period. Lazard Asset Management LLC boosted its stake in shares of Omnicell by 3.8% in the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after purchasing an additional 62,733 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Omnicell by 2.0% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after purchasing an additional 27,497 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Omnicell by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock worth $51,088,000 after buying an additional 11,424 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.
Wall Street Analysts Forecast Growth
OMCL has been the subject of a number of analyst reports. KeyCorp lowered their target price on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Zacks Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Craig Hallum reissued a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research report on Wednesday, April 29th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Omnicell in a research report on Tuesday, August 4th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $57.86.
Omnicell Price Performance
OMCL stock opened at $35.97 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The company’s 50-day moving average is $40.50 and its 200-day moving average is $39.89. The stock has a market capitalization of $1.64 billion, a PE ratio of 42.82, a price-to-earnings-growth ratio of 1.01 and a beta of 0.98. Omnicell, Inc. has a 1 year low of $29.06 and a 1 year high of $55.00.
Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. During the same period in the prior year, the business earned $0.45 EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts expect that Omnicell, Inc. will post 1.3 EPS for the current fiscal year.
About Omnicell
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
Read More
- Five stocks we like better than Omnicell
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL – Free Report).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
